February 14, 2022
Life Sciences
  • The FDA on Friday authorized a new monoclonal antibody treatment to treat mild to moderate COVID-19 symptoms. The drug, developed by Eli Lilly, should be used to treat patients ages 12 and older “for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.” The FDA said the drug is a critical tool for treatment as new variants continue to spread. (Press release here; Articles here and here)